As of 2025-07-05, the Intrinsic Value of Suparma Tbk PT (SPMA.JK) is 341.53 IDR. This SPMA.JK valuation is based on the model Discounted Cash Flows (Growth Exit 5Y). With the current market price of 252.00 IDR, the upside of Suparma Tbk PT is 35.50%.
The range of the Intrinsic Value is 259.79 - 475.29 IDR
Based on its market price of 252.00 IDR and our intrinsic valuation, Suparma Tbk PT (SPMA.JK) is undervalued by 35.50%.
| Range | Selected | Upside | |
| a | |||
| DCF (Growth 5y) | 259.79 - 475.29 | 341.53 | 35.5% |
| DCF (Growth 10y) | 306.64 - 548.82 | 398.81 | 58.3% |
| DCF (EBITDA 5y) | 381.86 - 519.76 | 430.89 | 71.0% |
| DCF (EBITDA 10y) | 379.63 - 572.28 | 454.55 | 80.4% |
| Fair Value | 261.44 - 261.44 | 261.44 | 3.75% |
| P/E | 285.77 - 439.30 | 343.05 | 36.1% |
| EV/EBITDA | 271.86 - 387.45 | 319.18 | 26.7% |
| EPV | 192.06 - 343.73 | 267.90 | 6.3% |
| DDM - Stable | 104.13 - 203.72 | 153.93 | -38.9% |
| DDM - Multi | 103.56 - 172.78 | 130.67 | -48.1% |
| Market Cap (mil) | 794,830.70 |
| Beta | 0.30 |
| Outstanding shares (mil) | 3,154.09 |
| Enterprise Value (mil) | 1,221,995.60 |
| Market risk premium | 7.88% |
| Cost of Equity | 17.35% |
| Cost of Debt | 5.50% |
| WACC | 11.70% |